全表观基因组关联研究提示MTRNR2L8低甲基化与大动脉粥样硬化性卒中相关
该研究对大动脉粥样硬化性卒中进行了全表观基因组关联分析,筛选阶段使用450K芯片(12例vs12例),发现1012个差异甲基化CpG位点(均值甲基化差异>5%,P<0.01)。在MTRNR2L8启动子区鉴定出差异甲基化区域(均值甲基化差异=-13.01%,P=8.86×10-14),并在两个验证队列(110:122和191:191)中用Sequenom EpiTYPER验证。基于MTRNR2L8显著变化CpG位点均值构建的诊断预测模型显示高特异度和敏感度(P<0.0001,AUC=0.774)。
要点
- 大动脉粥样硬化性卒中患者MTRNR2L8启动子区呈低甲基化(均值差异-13.01%)。
- 基于MTRNR2L8甲基化位点的诊断模型AUC=0.774,P<0.0001。
- 差异甲基化基因富集于心血管、代谢、神经和免疫相关功能基因簇(P<0.05)。
核心结论
- DNA甲基化在大动脉粥样硬化性卒中中起重要作用,MTRNR2L8甲基化是潜在治疗靶点和诊断生物标志物。
研究设计与样本
- 全表观基因组关联分析,筛选阶段使用Infinium HumanMethylation450芯片(病例:对照=12:12)。
- 差异甲基化位点在两个队列(病例:对照=110:122和191:191)中用Sequenom EpiTYPER验证。
主要发现
- 筛选阶段发现1012个差异甲基化CpG位点注释于672个基因(均值甲基化差异>5%,P<0.01)。
- MTRNR2L8启动子区差异甲基化区域均值甲基化差异=-13.01%,P=8.86×10-14。
- 基于MTRNR2L8显著变化CpG位点均值构建的诊断模型P<0.0001,曲线下面积=0.774。
关键数值与推荐
- 差异甲基化CpG位点筛选标准:均值甲基化差异>5%且P<0.01。
- 功能富集分析显示差异甲基化基因富集于心血管、代谢、神经和免疫相关功能基因簇(P<0.05)。
临床怎么用
- MTRNR2L8甲基化有望作为大动脉粥样硬化性卒中的诊断生物标志物。
- MTRNR2L8甲基化可能成为卒中治疗的潜在靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- Ischemic stroke, a complex and heterogeneous disease, is the second leading cause of death worldwide. Genetic factors and epigenetic modification contribute to the pathogenesis of this disease. However, the effects of epigenetic factors on this disease have not been systematically investigated. Our study was designed to identify methylation alterations in large-artery atherosclerotic stroke. Methods- We conducted an epigenome-wide association analysis of large-artery atherosclerotic stroke using an Infinium HumanMethylation450 array (cases:controls=12:12), and the differentially methylated loci were validated in 2 cohorts (cases:controls, 110:122 and 191:191, respectively) using a Sequenom EpiTYPER assay. Results- In the screening stage, 1012 differentially methylated CpG sites annotated in 672 genes were found to be significantly associated with large-artery atherosclerotic stroke (mean methylation difference >5%, P<0.01). Disease, Gene Ontology, and pathway analysis highlighted the enrichment of these differentially methylated genes in cardiovascular, metabolic, neurological and immune-related functional gene clusters ( P<0.05). We identified a differentially methylated region in the promoter of a humanin gene ( MTRNR2L8, mean methylation difference=-13.01%, P=8.86×10-14). We constructed a diagnostic prediction model that was based on the mean number of significantly changed CpG loci in MTRNR2L8 and showed high diagnostic specificity and sensitivity ( P<0.0001, area under the curve=0.774). Conclusions- Together, these findings demonstrate that DNA methylation plays an important role in large-artery atherosclerotic stroke and that methylation of MTRNR2L8 is a potential therapeutic target and diagnostic biomarker for stroke.
引用
- Shen Y, Peng C, Bai Q, et al. Epigenome-Wide Association Study Indicates Hypomethylation of MTRNR2L8 in Large-Artery Atherosclerosis Stroke. Stroke. 2019. PMID: 31084332. doi:10.1161/STROKEAHA.118.023436
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。